Can urinary PCA3 Supplement PSA in the early detection of prostate cancer?

Journal of Clinical Oncology

Volumn 32, Issue 36, 2014, Pages 4066-4072

  Wei, John T ^a   Feng, Ziding ^b   Partin, Alan W ^d   Brown, Elissa ^b   Thompson, Ian ^f   Sokoll, Lori ^d   Chan, Daniel W ^d   Lotan, Yair ^g   Kibel, Adam S ^h   Busby, J Erik ^j   Bidair, Mohamed ^k   Lin, Daniel W ^c   Taneja, Samir S ^l   Viterbo, Rosalia ^m   Joon, Aron Y ^b   Dahlgren, Jackie ^b   Kagan, Jacob ^e   Srivastava, Sudhir ^e   Sanda, Martin G ⁱ  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h HARVARD UNIVERSITY   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF SOUTH CAROLINA   (United States)

^k San Diego Arthritis Medical Clinic   (United States)

^l NEW YORK UNIVERSITY   (United States)

^m FOX CHASE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; AGED; BIOPSY; BLOOD; EARLY CANCER DIAGNOSIS; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATIC NEOPLASMS; URINE;

AGED; ANTIGENS, NEOPLASM; BIOPSY; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84916237853     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.8505     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
3. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319, 2009
4. Miller DC, Gruber SB, Hollenbeck BK, et al: Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98:1134-1141, 2006
5. Chou R, Croswell JM, Dana T, et al: Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Int Med 155:762-771, 2011
6. Basch E, Oliver TK, Vickers A, et al: Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 30:3020-3025, 2012
7. Greene KL, Albertsen PC, Babaian RJ, et al: Prostate specific antigen best practice statement: 2009 update. J Urol 182:2232-2241, 2009
8. Carter HB, Albertsen PC, Barry MJ, et al: American Urological Association (AUA) Guideline: Early Detection of Prostate Cancer, 2013. http://www.auanet.org/common/pdf/education/clinical-guidance/Prostate-Cancer-Detection.pdf
9. Morote Robles J, Ruibal Morell A, Palou Redorta J, et al: Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: A comparative study. Eur Urol 14:360-366, 1988
10. Pinkhasov GI, Lin YK, Palmerola R, et al: Complications following prostate needle biopsy requiring hospital admission or emergency department visits: Experience from 1000 consecutive cases. BJU Int 110:369-374, 2012
11. Zaytoun OM, Anil T, Moussa AS, et al: Morbidity of prostate biopsy after simplified versus complex preparation protocols: Assessment of risk factors. Urology 77:910-914, 2011
12. Catalona WJ, Partin AW, Slawin KM, et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 279:1542-1547, 1998
13. Stenman UH, Leinonen J, Alfthan H, et al: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222-226, 1991
14. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a communitybased population of healthy men: Establishment of age-specific reference ranges. JAMA 270:860-864, 1993
15. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220, 1992
16. Catalona WJ, Partin AW, Sanda MG, et al: A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185:1650-1655, 2011
17. Sokoll LJ, Sanda MG, Feng Z, et al: A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 19:1193-1200, 2010
18. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al: DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59:5975-5979, 1999
19. Hessels D, Klein Gunnewiek JM, van Oort I, et al: DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44:8-16, 2003
20. Nakanishi H, Groskopf J, Fritsche HA, et al: PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol 179:1804-1810, 2008
21. Fradet Y, Saad F, Aprikian A, et al: uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64:311-316, 2004
22. Groskopf J, Aubin SM, Deras IL, et al: APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52:1089-1095, 2006
23. Tinzl M, Marberger M, Horvath S, et al: DD3PCA3 RNA analysis in urine: A new perspective for detecting prostate cancer. Eur Urol 46:182-187, 2004
24. van Gils MP, Hessels D, van Hooij O, et al: The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination: A Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 13:939-943, 2007
25. Marks LS, Fradet Y, Deras IL, et al: PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69:532-535, 2007
26. Tombal B, Ameye F, de la Taille A, et al: Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3: A systematic analysis of expert opinion. World J Urol 30:251-256, 2012
27. Haese A, de la Taille A, van Poppel H, et al: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54:1081-1088, 2008
28. Ramos CG, Valdevenito R, Vergara I, et al: PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination: First Latin American experience. Urol Oncol 31:1522-1526, 2013
29. Hansson L, Hedner T, Dahlöf B: Prospective randomized open blinded end-point (PROBE) study: A novel design for intervention trials - Prospective Randomized Open Blinded End-Point. Blood Press 1:113-119, 1992
30. Day JR, Jost M, Reynolds MA, et al: PCA3: From basic molecular science to the clinical lab. Cancer Lett 301:1-6, 2011
31. Kawachi MH, Bahnson RR, Barry M, et al: NCCN clinical practice guidelines in oncology: Prostate cancer early detection. J Natl Compr Canc Netw 8:240-262, 2010
32. Deras IL, Aubin SM, Blase A, et al: PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 179:1587-1592, 2008
33. Wang R, Chinnaiyan AM, Dunn RL, et al: Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 115:3879-3886, 2009
34. Pepe MS, Feng Z, Longton G, et al: Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility. Stat Med 28:762-779, 2009
35. Thompson IM, Ankerst DP, Chi C, et al: Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98:529-534, 2006
36. Eyre SJ, Ankerst DP, Wei JT, et al: Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol 182:2653-2658, 2009
37. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44:837-845, 1988
38. Huang Y, Sullivan Pepe M, Feng Z. Evaluating the predictiveness of a continuous marker. Biometrics 63:1181-1188, 2007
39. Pepe MS, Feng Z, Huang Y, et al: Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol 167:362-368, 2008